RENOPROTECTIVE EFFECTS OF BROMOCRIPTINE WITH ANALYSIS OF RENAL MARKERS IN DIABETIC RATS: A MORPHOLOGICAL AND HISTOPATHOLOGICAL EVALUATION IN KIDNEY TISSUES
Main Article Content
Keywords
Bromocriptine, antidiabetic, diabetic nephropathy, urea, creatinine, electrolytes.
Abstract
Background: Diabetes is one of the disorders that require life time management. Oral hypoglycemic are widely utilized by diabetic individuals to control sugar level. An abnormality in kidney function
markers is one of the major problems.
Objectives: Bromocriptine activates dopamine receptors in the kidney, which can help improve renal function, act as therapeutic agent for patients with diabetic nephropathy and used as part of a renal protective strategy to prevent or slow kidney disease progression.
Study Design: Experimental.
Place and Duration: Study was conducted at Karachi University, Department of Pharmacology, from November 2022 to April 2023.
Methods: An in vivo study was conducted to evaluate the effects of bromocriptine on diabetes and kidney damage. Blood samples from normal and diabetic male rats were analyzed for kidney markers i.e urea, creatinine, electrolytes and compared to a control diabetic group. The results showed that bromocriptine effectively reversed diabetic nephropathy in the diabetic-induced group, demonstrating its potential in managing diabetes and protecting the kidney.
Results: In this, bromocriptine was found to improve blood glucose level and significantly normalize renal markers compared to control diabetic group. Moreover, diabetic induced group caused substantial damage to renal architecture, which was notably reversed by bromocriptine. In conclusion, bromocriptine demonstrates potential in treating diabetes and protecting the kidney from diabetes-induced damage Conclusion: The studied concluded that bromocriptine have marked good antidiabetic activity and protecting the kidney from diabetic complications.
References
2. Honeycutt AA, Boyle JP, Broglio KR, Thompson TJ, Hoerger TJ, Geiss LS, et al. A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050. Health Care Manag Sci. 2003;6:155–64. doi: 10.1023/a:1024467522972.
3. Rathmann W, Giani G. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:2568–9. doi: 10.2337/diacare.27.10.2568
4. Chen, J., et al. (2015). Bromocriptine attenuates renal fibrosis in chronic kidney disease. American Journal of Nephrology, 41(2), 147-156.
5. Ishimitsu, T., et al. (2009). Bromocriptine improves renal function and reduces oxidative stress in rats with chronic kidney disease. European Journal of Pharmacology, 615(1-3), 153-161.
6. Morales, A. I., et al. (2018). Bromocriptine improves renal function and reduces inflammation in a rat model of chronic kidney disease. Journal of Pharmacology and Experimental Therapeutics, 366(2), 241-251.
7. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ (November 2002). "Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor". J Pharmacol Exp Ther. 303 (2): 805–14.
8. Bakris, G. L., et al. (2004). Bromocriptine reduces proteinuria in patients with chronic kidney disease. Journal of the American Society of Nephrology, 15(11), 2911-2918.de Leeuw van Weenen JE, Parlevliet ET, Maechler P, Havekes LM, Romijn JA, Ouwens DM, et al. (June 2010). "The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells". Biochemical Pharmacology. 79 (12): 1827–36.
9. Luo S, Luo J, Cincotta AH: Association of the antidiabetic effects of bromocriptine with a shift in the daily rhythm of monoamine metabolism within the suprachiasmatic nuclei of the Syrian hamster. Chronobiol Int. 2000, 17 (2): 155-172. 10.1081/CBI-100101040.
10. Luo S, Meier AH, Cincotta AH: Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters. Neuroendocrinology. 1998, 68 (1): 1-10. 10.1159/000054344.
11. Bina KG, Cincotta AH: Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice. Neuroendocrinology. 2000, 71 (1): 68-78.
12. Hansen B, Shaffrir E, Cincotta AH. Hypothalamic role in the insulin resistance syndrome. In Insulin Resistance Syndrome. Hansen B, Shaffrir E, Eds. London, Taylor and Francis, 2002, p. 271–312
13. Linda Cloete .Diabetes mellitus: an overview of the types, symptoms, complications and management: Nurs Stand. 2022 Jan 5;37(1):61-66.
14. Barbara Fletcher , Meg Gulanick, Cindy Lamendola.Risk factors for type 2 diabetes mellitus: J Cardiovasc Nurs. 2002 Jan;16(2):17-23
15. H Flórez .Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations: Invest Clin. 1997 Mar;38(1):39-52
16. H Florez , H Valbuena, E Ryder, E Rincón, G Campos, S Castillo, J González, V Fernández, X Raleigh, M E Gómez.Dyslipidemia and hyperinsulinemia in normoglycemic-obese relatives of patients with non-insulin dependent diabetes mellitus : Invest Clin. 1995 Sep;36(3):131-47.
17. G M Reaven .Pathophysiology of insulin resistance in human disease: Physiol Re. 1995 Jul;75(3):473-86.
18. Cincotta AH, Meier AH, Cincotta Jr M: Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999, 8 (10): 1683-1707.
19. Chen, J., et al. (2015). Bromocriptine attenuates renal fibrosis in chronic kidney disease. American Journal of Nephrology, 41(2), 147-156.
20. Felicitas Lopez Vicchi , Guillermina Maria Luque , Belen Brie , Juan Patricio Nogueira , Isabel Garcia Tornadu , Damasia Becu-Villalobos . Dopaminergic drugs in type 2 diabetes and glucose homeostasis: Pharmacol Res. 2016 Jul:109:74-80.
21. Sarah N Framnes-DeBoer , Ellen Bakke 1, Suma Yalamanchili 2, Hannah Peterson, Darleen A Sandoval , Randy J Seeley 3, Deanna M Arble 1. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor :Am J Physiol Endocrinol Metab.2020 Jan 1;318(1):E62-E71.
22. Fletcher, Meier AH, Cincotta Jr M: Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. Expert Opin Investig Drugs. 1999, 8 (10): 1683-1707.
23. Chen, J., et al. (2015). Bromocriptine attenuates renal fibrosis in chronic kidney disease. American Journal of Nephrology, 41(2), 147-156.
24. Felicitas Lopez Vicchi , Guillermina Maria Luque , Belen Brie , Juan Patricio Nogueira , Isabel Garcia Tornadu , Damasia Becu-Villalobos . Dopaminergic drugs in type 2 diabetes and glucose homeostasis: Pharmacol Res. 2016 Jul:109:74-80.
25. Sarah N Framnes-DeBoer , Ellen Bakke 1, Suma Yalamanchili 2, Hannah Peterson, Darleen A Sandoval , Randy J Seeley 3, Deanna M Arble 1. Bromocriptine improves glucose tolerance independent of circadian timing, prolactin, or the melanocortin-4 receptor :Am J Physiol Endocrinol Metab.2020 Jan 1;318(1):E62-E71.
26. Carey, R. M., et al. (2012). Dopamine receptors and the kidney: role in renal function and disease. American Journal of Physiology-Renal Physiology, 302(11), F1341-F1353. doi: 10.1152/ajprenal.00648.2011
27. Li, Z., et al. (2015). Bromocriptine reduces serum creatinine and urea levels in patients with chronic kidney disease: a meta-analysis. International Journal of Clinical Pharmacology and Therapeutics, 53(9), 753-761.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Sonia Khan
Associate Professor, Department of Pharmacology, Al-Tibri Medical College, Karachi, Pakistan
Syed Shahzil Ali Shah
Final year MBBS Student, Ziauddin Medical College, Karachi, Pakistan
Asma Shabbir
Associate Professor, Department of Pathology, Jinnah Sindh Medical University, Karachi, Pakistan
Shahid Maqbool Korai
Assistant Professor, Department of Anatomy, Al-Tibri Medical College, Karachi, Pakistan
Naveen Aleem
Lecturer, Department of Anatomy, Al-Tibri Medical College, Karachi, Pakistan
Rubbiya Javed
Lecturer, Department of Anatomy, Al-Tibri Medical College, Karachi, Pakistan
Sajeela Furqanullah
Lecturer, Department of Anatomy, Al-Tibri Medical College, Karachi, Pakistan
Marvi
Assistant Professor, Department of Pharmacy, University of Baluchistan, Quetta, Pakistan.